Enhancement of fibronectin fibrillogenesis and bone formation by basic fibroblast growth factor via protein kinase C-dependent pathway in rat osteoblasts.
Fibronectin (Fn) is involved in early stages of bone formation and basic fibroblast growth factor (bFGF) is an important factor regulating osteogenesis. We here found that bFGF enhanced extracellular assembly from either endogenously released or exogenously applied soluble Fn in primary cultured osteoblasts. bFGF increased protein levels of Fn using Western blotting analysis. Protein kinase C (PKC) inhibitors such as H7, 3-[1-[3-(amidinothio)propyl-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleimide (Bisindolylmaleimide IX), methanesulfonate (Ro 318220,) or 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c] carbazole (Gö 6976) antagonized the increase of Fn protein by bFGF. Treatment of osteoblasts with bFGF increased membrane translocation of various isoforms of PKC, including alpha, beta, epsilon, and delta. However, treatment with antisense of various PKC isoforms demonstrated that alpha and beta isozymes play important roles in the enhancement action of bFGF on Fn assembly. Down-regulation of PKC by prolonged treatment with 1 microM 12-O-tetradecanoylphorbol-13 acetate for 24 h inhibited the potentiating action of bFGF. It has been reported that alpha5beta1 integrin is related to Fn fibrillogenesis, and immunocytochemistry showed that bFGF treatment increased the clustering of alpha5 integrins. Flow cytometry analysis demonstrated that bFGF increased cell surface expression of alpha5 and beta1 integrins and PKC inhibitors antagonized the increase by bFGF. Local administration of bFGF into the metaphysis of the tibia via the implantation of a needle cannula significantly increased the protein levels of Fn in the area of trabecular spongiosa, which was inhibited by coadministration of PKC inhibitors. Furthermore, local injection of bFGF increased the bone volume of secondary spongiosa in tibia, which was significantly antagonized by PKC inhibitors. These results suggest that bFGF increased bone formation and Fn fibrillogenesis both in vitro and in vivo via PKC-dependent pathway.
Tang
Chih-Hsin
CH
Department of Pharmacology, College of Medicine, National Taiwan University, 1, Sec. 1, Jen-Ai Road, Taipei, Taiwan.
Yang
Rong-Sen
RS
Huang
Tsang-Hai
TH
Liu
Shing-Hwa
SH
Fu
Wen-Mei
WM
D000818:Animals; D002478:Cells, Cultured; D016222:Fibroblast Growth Factor 2 / Q000502:physiology*; D005353:Fibronectins / Q000502:physiology*; D016023:Integrins / Q000378:metabolism; D010006:Osteoblasts / Q000201:enzymology / Q000378:metabolism*; D010012:Osteogenesis / Q000502:physiology*; D011493:Protein Kinase C / Q000378:metabolism*; D051381:Rats; D013977:Tibia / Q000502:physiology
D005353:Fibronectins; D016023:Integrins; D016222:Fibroblast Growth Factor 2; D011493:Protein Kinase C